Prevalence of treated hyper- and hypo-thyroidism and sociodemographic and geographic disparities in France in 2020
European Thyroid Journal · 01.06.2025 · 14 (3)
DOI: 10.1530/etj-25-0041 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Thyroid Journal, online erschienen am 06.06.2025. Verfasst von Joël Coste und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Non-Communicable Diseases and Injuries, French Public Health Agency (Santé publique France), Saint-Maurice, France. Hauptthemen laut MEDLINE: Hypothyroidism, Hyperthyroidism. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Healthcare claims data are increasingly used to investigate the epidemiology of benign thyroid diseases. Here, we estimate the prevalence of treated hyper- and hypo-thyroidism and assess the potential sociodemographic and geographic disparities in France in 2020, given the country’s poor epidemiological knowledge of these conditions.
Methods
We used the French national healthcare data system, which covers nearly the entire population residing in France (over 67 million inhabitants in metropolitan and overseas departments). Prevalent cases were identified based on patients’ long-term disease status, hospitalisation for hyper- and hypo-thyroidism and reimbursements for thyroid hormones, antithyroid drugs, iodine-131 and thyroid surgery. Thyroid-stimulating hormone, antithyroid antibodies and previous therapy for thyroid cancer and hyperthyroidism were considered to characterise the origin and surveillance of hypothyroidism.
Results
In 2020, we identified 112,992 and 2,986,333 cases of treated hyper- and hypo-thyroidism, respectively, with an overall prevalence of 0.17 and 4.45 per 100 inhabitants. Marked differences were observed in terms of sex, age group and geographic area (department) for both conditions and deprivation level of the place of residence for hyperthyroidism only. The proportion of hypothyroidism following previous therapy for thyroid cancer or hyperthyroidism was less than 10%. Adequate monitoring (thyroid-stimulating hormone checked in the past year) occurred in 73.7% of hypothyroid subjects, with large variations across departments.
Conclusions
This study provides prevalence estimates of treated hyper- and hypo-thyroidism at the national and departmental levels in France and improves epidemiological knowledge of both conditions. It also supports using healthcare claims data for their epidemiological surveillance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Non-Communicable Diseases and Injuries, French Public Health Agency (Santé publique France), Saint-Maurice, France.
- Data Science Division, French Public Health Agency (Santé publique France), Saint-Maurice, France.
- Endocrinologie, Université Paris-Cité, Paris, France.
- Académie Nationale de Médecine, Paris, France.
- Endocrinologie, Université de Lille, Lille, France.
ORCID-Profile: Joël Coste
Zitieren
APA
Coste, J., Mandereau-Bruno, L., Bertagna, X., & Wémeau, J. L. (2025). Prevalence of treated hyper- and hypo-thyroidism and sociodemographic and geographic disparities in France in 2020. European Thyroid Journal, 14(3). https://doi.org/10.1530/etj-25-0041
Vancouver
Coste J, Mandereau-Bruno L, Bertagna X, Wémeau JL. Prevalence of treated hyper- and hypo-thyroidism and sociodemographic and geographic disparities in France in 2020. European Thyroid Journal. 2025;14(3). doi:10.1530/etj-25-0041
BibTeX
@article{Coste2025,
author = {Coste, Joël and Mandereau-Bruno, Laurence and Bertagna, Xavier and Wémeau, Jean-Louis},
title = {Prevalence of treated hyper- and hypo-thyroidism and sociodemographic and geographic disparities in France in 2020},
journal = {European Thyroid Journal},
year = {2025},
volume = {14},
number = {3},
doi = {10.1530/etj-25-0041}
}
EUVIMED